Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

201991 citationsJournal Articlegold Open Access

Authors

Melanie D. Whittington · University of Colorado Anschutz Medical Campus

R. Brett McQueen · University of Colorado Anschutz Medical Campus

Daniel A. Ollendorf · Institute for Clinical and Economic Review

Varun Kumar · Institute for Clinical and Economic Review

Richard H. Chapman · Institute for Clinical and Economic Review

Jeffrey A. Tice · University of California, San Francisco

Abstract

Treatment with axicabtagene ciloleucel appears to be associated with incremental gains in survival over chemotherapy. The range in projected long-term survival was wide and reflected uncertainty owing to limited follow-up data. Cost-effectiveness is associated with long-term survival, with further evidence needed to reduce uncertainty.

Topics & Keywords

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Integrated Circuits and Semiconductor Failure Analysis

Publication Details

Published in: JAMA Network Open

Volume 2, Issue 2, pp. e190035-e190035

DOI: 10.1001/jamanetworkopen.2019.0035

Field-Weighted Citation Impact: 6.35

Command Palette

Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma

Authors

Abstract

Topics & Keywords

Publication Details